bluebird bio
NEWS
Cambridge, Mass.-based bluebird bio and Gritstone Oncology inked a deal to combine gene and cell therapies to target cancer. This morning California-based Gritstone said it will leverage its artificial intelligence platform, dubbed EDGE, to analyze specific tumor types for the collaboration.
Express Scripts is already known for its role of bringing prescriptions to the doors of consumers. Now the company is moving into a new area of providing medicines—expensive gene therapies.
This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or biotech industries.
Regeneron Pharmaceuticals and bluebird bio are teaming up. The companies will combine their expertise in the battle against cancer by leveraging Regeneron’s VelociSuite platform with bluebird’s cell therapy technologies to develop new cell therapies for patients.
Bluebird bio’s LentiGlobin gene therapy is increasing hemoglobin levels in anemia patients battling sickle cell disease and beta thalassemia, which reduces the need for blood transfusions in those patients.
Within the next six years, the multiple myeloma market is projected to be $37.5 billion – an incredible growth of $30 billion since 2015, when the market was valued at about $7.5 billion.
AveXis, a Novartis company based in Illinois, is investing $55 million to build a new manufacturing facility in Durham, North Carolina.
Medigene and bluebird bio announced they are expanding a strategic research and development collaboration inked in September 2016.
Bluebird has been chosen to receive the Cooley Anemia Foundation’s Humanitarian of the Year Award at its annual gala in June.
JOBS
IN THE PRESS
In patients who were at least six months post-treatment with LentiGlobin for SCD, median level of abnormal sickle hemoglobin (HbS) was reduced to ≤50 percent of total Hb
bluebird bio, Inc. announced that the company will host a live webcast to review new data presented at the European Hematology Association Annual Meeting, and to discuss the approval of ZYNTEGLO® on Friday, June 14 at 8:00 a.m. ET.
ZYNTEGLO is the first gene therapy approved for transfusion-dependent β-thalassemia (TDT)
bluebird bio, Inc. announced that the Company will hold a conference call to discuss data presented at the European Hematology Association Annual Meeting on Friday, June 14 at 8:00 am ET.
Additional follow-up from the completed Phase 1/2 Northstar (HGB-204) study of LentiGlobin in adolescents and adults with TDT
New Collaboration with Seattle Children’s Research Institute Targets New Immunotherapy Approaches to Acute Myeloid Leukemia
bluebird bio, Inc. announced that the Company will host an Analyst Day, Thursday, May 9, at 8:30 am ET at The Maxwell Hotel NYC, New York, NY.
Company hosting Analyst Day on May 9, 2019 focused on research and commercial strategies
The manuscript, “Anti-BCMA CAR T Cell Therapy bb2121 in Relapsed/Refractory Multiple Myeloma”, published in NEJM includes key safety and efficacy results from the dose escalation and first expansion cohort, including a minimum of six months follow up on all subjects.
bluebird bio, Inc., has appointed Joanne Smith-Farrell, Ph.D., to chief business officer.